Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
anavex life sciences股份上漲，在公司宣佈來自IIb/III期研究的新數據後顯示，Blarcamesine，每日一次口服，通過上游SIGMAR1激活呈現預設臨床療效。
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
Anavex Life Sciences的股價走高，此前該公司公佈了Iib/III期研究的新數據，該數據顯示，每天口服一次的布拉卡梅辛通過上游 SIGMAR1 激活顯示出預先規定的臨床療效。
資訊熱榜
更新時間